



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/533,595

04/27/2006

Todd Charlton Sacktor

15878

6263

272 7590 04/11/2008  
SCULLY, SCOTT, MURPHY & PRESSER, P.C.  
400 GARDEN CITY PLAZA  
SUITE 300  
GARDEN CITY, NY 11530

EXAMINER

MACFARLANE, STACEY NEE

ART UNIT

PAPER NUMBER

1649

MAIL DATE

DELIVERY MODE

04/11/2008

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/533,595	<b>Applicant(s)</b> SACKTOR ET AL.	
	<b>Examiner</b> STACEY MACFARLANE	<b>Art Unit</b> 1649	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 25 February 2008.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-9, 12, 14-16, 18-37 is/are pending in the application.
- 4a) Of the above claim(s) 1-9, 12, 14-16, 18-21 and 24-37 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 22 and 23 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 02 May 2005 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |                                                                                        |                                                                   |
|----------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)            | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | Paper No(s)/Mail Date. _____                                      |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>6/20/2005; 4/16/2007; 4/01/2008</u> .                         | 6) <input type="checkbox"/> Other: _____                          |



## **DETAILED ACTION**

### ***Election/Restrictions***

1. Applicant's election with traverse of Group V, claims 22 and 23, in the reply filed on February 25, 2008 is acknowledged. The traversal is on the ground(s) that Examiner fails to provide any specific reason to allege that Groups I-X do not relate to a single general inventive concept under PCT Rule 13.1. This is not found persuasive because according to PCT Rule 13.2, unity of invention exists only when there is a shared same or corresponding special technical feature among the claimed inventions. Each group has a different special technical feature not shared by the remaining groups.

The special technical feature of Group I is not a product but is a method of diagnosing a nervous system disorder using an antibody.

The special technical feature of Group II is a method of diagnosing a nervous system disorder using a nucleic acid molecule.

The special technical feature of Group III is an assay a method of identifying a compound that modulates aPKC activity.

The special technical feature of Group IV is a method of treating a nervous system disorder comprising gene therapy.

The special technical feature of Group V is the first claimed product, drawn to an aPKC antibody. Additionally, the PCT rules provide for the examination of the first claimed product, the first claimed method of making that product, and the first claimed method of using that product in one application, but do not provide for the examination

Art Unit: 1649

of multiple products or unrelated methods. For example, the claimed methods use different steps and different reagents corresponding to the distinct technical features, and exhibit different effects, functions and outcomes. The special technical features of Groups I-IV encompass multiple methods and Groups II, II and IV are not specifically drawn to use of a single claimed product. Thus, the claims inventions fail to meet the requirements of Unity of invention before the International Searching Authority pursuant to Rule 13.2 and 37 C.F.R. § 1.475 (a). Accordingly, Groups I-X are not so linked by the same or a corresponding special technical feature as to form a single general inventive concept.

The requirement is still deemed proper and is therefore made FINAL.

2. Claims 1-9, 12, 14-16, 18-21 and 24-37 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected inventions, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on February 25, 2008.
3. Claims 22 and 23 will be examined upon their merits in the instant Office Action.

### ***Claim Objections***

4. Claims 22 and 23 are objected to for the following informalities: the claims recite acronyms that are not spelled-out in their first use in the claims (i.e. aPKC and PKMζ). It would be remedial to amend the claim language to define the acronyms so that they are clearly understood what they stand for.

***Claim Rejections - 35 USC § 101***

5. 35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 22 and 23 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claims do not sufficiently distinguish over antibodies that exist in nature. Antibodies are produced within an animal in response to an antigen stimulus and, as such, are naturally occurring products that are considered non-statutory subject matter. See *Diamond v. Chakrabarty*, 447 U.S. 303, 206 USPQ 193 (1980) and MPEP 2105. Claims should be amended to indicate the hand of the inventor, for example by insertion of "Purified" as taught by the recitation of "affinity-purified" on page 40 of the specification.

***Claim Rejections - 35 USC § 112***

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claim 22 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

8. Claim 22 is drawn to an antibody which binds to “an isoform of an aPKC” molecule or “a functional derivative thereof”. The claim does not require that the “isoform” or “functional derivative” possess any particular conserved structure or other disclosed distinguishing feature. Thus, the claim is drawn to antibodies that bind to a genus of molecules that are merely defined by function and the instant specification fails to describe the entire genus of molecules that are encompassed by these claims.

In making a determination of whether the application complies with the written description requirement of 35 U.S.C. 112, first paragraph, it is necessary to understand what Applicant has possession of and what Applicant is claiming. From the specification, it is clear that Applicant is in possession of specific examples of aPKC isoforms (i. e. PKM $\zeta$  I/II) and PKC1/ $\lambda$  on page 1 of specification). Claim 22, however, is drawn to an antibody the binds any functional derivative of any isoform of an aPKC molecule. Thus, the claims are not limited to specific molecules with known structures. The claims merely require the molecules be functional.

To provide adequate written description and evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof. In the instant case, the only factor present in the claim is a recitation of activity. There is not even identification of any particular portion of the structure that must be conserved for activity. As stated above, it is not even clear what

Art Unit: 1649

molecules are encompassed by the terms “isoform” and “functional derivative”. The specification does not provide a complete structure of these derivatives and fails to provide a representative number of species for the recited genus. Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus.

*Vas-Cath Inc. v. Mahurkar*, 19USPQ2d 1111, the court clearly states “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of *the invention*. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed*.” (See page 1117.) The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See *Vas-Cath* at page 1116). As discussed above, the skilled artisan cannot envision the detailed chemical structures of aPKC isoforms nor of any functional derivatives thereof, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of identifying activity. Adequate written description requires more than a mere recitation of activity as part of the invention and a reference to a potential method of isolating or screening. The compound itself is required. See *Fiers v Revel*, 25 USPQ2d 1601 at 1601 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016.

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481 at 1483. In *Fiddes*, claims directed to mammalian FGF’s were found to



be unpatentable due to lack of written description for that broad class. The specification only provided for the bovine sequence.

Applicant is reminded that Vas-Cath makes clear that the written description provision of 35 U.S.C. § 112 is severable from its enablement provision (see page 1115).

### ***Claim Rejections - 35 USC § 102***

9. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

10. Claims 22 and 23 are rejected under 35 U.S.C. 102(b) as being anticipated by Naik et al. *Journal of Comparative Neurology*, 426: 243-258, 2000.

11. Claims 22 and 23 are drawn to an antibody which binds to an isoform of an aPKC molecule or a functional derivative thereof, wherein the aPKC is PKM $\zeta$ .

12. The Naik prior art teaches PKC primary antisera that binds to PKM $\zeta$  (page 245, **Immunoblotting** and **Immunocytochemical staining**). Thus, the prior art fully anticipates the antibody product of the claims.

### ***Conclusion***

13. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to STACEY MACFARLANE whose telephone number is

Art Unit: 1649

(571)270-3057. The examiner can normally be reached on M,W and ALT F 7 am to 3:30, T & R 5:30 -5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Stucker can be reached on (571) 272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Stacey MacFarlane  
Examiner  
Art Unit 1649

/Olga N. Chernyshev, Ph.D./  
Primary Examiner, Art Unit 1649